Entering text into the input field will update the search result below

Kite Pharma collaborates with Cell Design Labs on CAR-T "on/off switch"

Jun. 02, 2016 9:20 AM ETKite Pharma (KITE) StockBy: Douglas W. House, SA News Editor1 Comment
  • Kite Pharma (NASDAQ:KITE) inks a research collaboration and license agreement with Cell Design Labs for the development of next-generation chimeric antigen receptor (CAR) candidates that incorporate Cell Design's molecular "on/off switch" technology.
  • The switch technology uses small molecules to build and control cell signaling networks which can "turn off" the CAR in the absence of the small molecule, giving doctors the ability to rapidly control and reverse the activity of CAR T-cells, an important capability if a patient experiences a "cytokine storm", a massive release of cytokines in the bloodstream which can be life-threatening. It occurs when the CAR-T therapy, in essence, works too well.
  • Under the terms of the agreement, Cell Design will receive an upfront payment of $2M, up to $56.5M in milestones, up to $9M to support research and tiered single-digit royalties on a product-by-product and country-by-country basis. Kite will also make an additional $6M equity investment in Cell Design, following its $1M investment made in December 2015.

Recommended For You

Related Stocks

SymbolLast Price% Chg
KITE--
Kite Pharma